Home LiteratureArticle Details
PMID: 18345021 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.

Nature reviews. Microbiology ·Vol. 6 ·No. 5 ·2008-05-00 ·Pages 349-62

Wells JM, Mercenier A

Abstract

Studies of lactic acid bacteria (LAB) as delivery vehicles have focused mainly on the development of mucosal vaccines, with much effort being devoted to the generation of genetic tools for antigen expression in different bacterial locations. Subsequently, interleukins have been co-expressed with antigens in LAB to enhance the immune response that is raised against the antigen. LAB have also been used as a delivery system for a range of molecules that have different applications, including anti-infectives, therapies for allergic diseases and therapies for gastrointestinal diseases. Now that the first human trial with a Lactococcus strain that expresses recombinant interleukin-10 has been completed, we discuss what we have learnt, what we do not yet understand and what the future holds for therapy and prophylaxis with LAB.

MeSH Terms
Animals Drug Delivery Systems/methods Humans Immunity, Mucosal Lactic Acid/biosynthesis Lactobacillus/genetics,immunology Mice Mucous Membrane/microbiology Recombinant Proteins/genetics,immunology,therapeutic use Streptococcaceae/genetics,immunology Vaccines, DNA/genetics,immunology,therapeutic use
Chemicals
Recombinant Proteins Vaccines, DNA Lactic Acid
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wells Jerry M
Host-Microbe Interactomics, University of Wageningen, Animal Sciences Department, P.O. BOX 338, 6700 AH, Wageningen, The Netherlands. [email protected]
Mercenier Annick
References (102)
102 references, click to expand
  1. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice.
    Int Immunopharmacol. 2006 Apr;6(4):610-5 PMID: 16504924
  2. Gene expression systems for lactic acid bacteria.
    Curr Opin Microbiol. 1999 Jun;2(3):289-95 PMID: 10383867
  3. Demonstration of safety of probiotics -- a review.
    Int J Food Microbiol. 1998 Oct 20;44(1-2):93-106 PMID: 9849787
  4. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
    Gastroenterology. 2007 Aug;133(2):517-28 PMID: 17681173
  5. Biological safety concepts of genetically modified live bacterial vaccines.
    Vaccine. 2007 Jul 26;25(30):5598-605 PMID: 17239999
  6. Probiotics and safety.
    Am J Clin Nutr. 2001 Feb;73(2 Suppl):465S-470S PMID: 11157359
  7. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    J Med Virol. 2006 Feb;78(2):141-7 PMID: 16372284
  8. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence.
    Vaccine. 2002 Sep 10;20(27-28):3304-9 PMID: 12213400
  9. Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice.
    Clin Vaccine Immunol. 2007 Mar;14(3):226-33 PMID: 17202306
  10. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization.
    J Allergy Clin Immunol. 2007 Apr;119(4):952-9 PMID: 17316776
  11. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.
    AIDS. 2002 Jul 5;16(10):1351-6 PMID: 12131211
  12. Potential and opportunities for use of recombinant lactic acid bacteria in human health.
    Adv Appl Microbiol. 2004;56:1-64 PMID: 15566975
  13. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
    Gastroenterology. 2007 Sep;133(3):862-74 PMID: 17678918
  14. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis.
    Infect Immun. 2000 Jun;68(6):3251-60 PMID: 10816470
  15. The European LABDEL project and its relevance to the prevention and treatment of allergies.
    Allergy. 2007 Nov;62(11):1237-42 PMID: 17919137
  16. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice.
    Appl Environ Microbiol. 2003 Nov;69(11):6620-7 PMID: 14602621
  17. Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells.
    Appl Environ Microbiol. 2006 Nov;72(11):7091-7 PMID: 16963550
  18. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env.
    Blood. 2003 Jul 1;102(1):223-8 PMID: 12649143
  19. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria.
    Science. 2004 Mar 12;303(5664):1662-5 PMID: 15016999
  20. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice.
    Vaccine. 2001 Jul 16;19(28-29):3927-35 PMID: 11427267
  21. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.
    Microbes Infect. 2006 Apr;8(4):1016-24 PMID: 16549380
  22. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria.
    Vaccine. 2006 Aug 14;24(33-34):5931-6 PMID: 16814902
  23. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.
    Vaccine. 2003 Dec 8;22(1):87-95 PMID: 14604575
  24. Intranasal vaccines for protection against respiratory and systemic bacterial infections.
    Expert Rev Vaccines. 2007 Jun;6(3):419-29 PMID: 17542756
  25. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.
    Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4624-9 PMID: 17360574
  26. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.
    Infect Immun. 2004 May;72(5):2753-61 PMID: 15102785
  27. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.
    Infect Immun. 2001 Mar;69(3):1547-53 PMID: 11179325
  28. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis.
    FEMS Immunol Med Microbiol. 1996 Jun;14(2-3):167-77 PMID: 8809553
  29. Enhanced immunisation and expression strategies using bacterial spores as heat-stable vaccine delivery vehicles.
    Vaccine. 2007 Jan 4;25(2):356-65 PMID: 16920233
  30. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract.
    Aliment Pharmacol Ther. 2000 Jun;14(6):823-8 PMID: 10848668
  31. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine.
    Infect Immun. 1998 Jul;66(7):3183-9 PMID: 9632584
  32. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis.
    Appl Environ Microbiol. 1995 Apr;61(4):1627-9 PMID: 7747977
  33. Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency.
    Appl Environ Microbiol. 2002 Jun;68(6):3166-8 PMID: 12039786
  34. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract.
    Appl Environ Microbiol. 2004 Feb;70(2):1176-81 PMID: 14766603
  35. Use of attenuated bacteria as delivery vectors for DNA vaccines.
    Expert Rev Vaccines. 2007 Feb;6(1):97-110 PMID: 17280482
  36. Recent advances in the development of live, attenuated bacterial vectors.
    Curr Opin Mol Ther. 2005 Feb;7(1):62-72 PMID: 15732531
  37. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis.
    J Infect Dis. 2005 Oct 15;192(8):1441-9 PMID: 16170763
  38. Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice.
    J Allergy Clin Immunol. 1998 Jul;102(1):57-64 PMID: 9679848
  39. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement.
    J Exp Med. 2006 Dec 25;203(13):2841-52 PMID: 17145958
  40. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C.
    Vaccine. 1997 Apr-May;15(6-7):616-9 PMID: 9178460
  41. Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines.
    Appl Environ Microbiol. 2003 Dec;69(12):7281-8 PMID: 14660377
  42. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection.
    J Appl Microbiol. 2004;96(6):1347-53 PMID: 15139928
  43. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.
    Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11993-8 PMID: 16040799
  44. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge.
    Mol Microbiol. 1993 Jun;8(6):1155-62 PMID: 8361360
  45. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
    Science. 2000 Aug 25;289(5483):1352-5 PMID: 10958782
  46. Mucosal vaccines: the promise and the challenge.
    Nat Rev Immunol. 2006 Feb;6(2):148-58 PMID: 16491139
  47. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
    Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30 PMID: 9210678
  48. Recent advances in protein and peptide drug delivery systems.
    Curr Drug Deliv. 2007 Apr;4(2):141-51 PMID: 17456033
  49. Optimization and delivery of plasmid DNA for vaccination.
    Expert Rev Vaccines. 2006 Dec;5(6):803-25 PMID: 17184219
  50. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis.
    Nat Biotechnol. 1997 Jul;15(7):653-7 PMID: 9219268
  51. Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).
    World J Gastroenterol. 2005 Nov 28;11(44):6975-80 PMID: 16437602
  52. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.
    Antimicrob Agents Chemother. 2006 Oct;50(10):3250-9 PMID: 17005802
  53. Oral colonization and immune responses to Streptococcus gordonii: Potential use as a vector to induce antibodies against respiratory pathogens.
    Curr Opin Infect Dis. 2003 Jun;16(3):231-5 PMID: 12821813
  54. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.
    Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S20-3 PMID: 17582563
  55. Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria.
    Infect Immun. 2004 May;72(5):2731-7 PMID: 15102782
  56. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies.
    Nat Biotechnol. 2002 Jul;20(7):702-6 PMID: 12089555
  57. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria.
    Nat Immunol. 2001 Apr;2(4):361-7 PMID: 11276208
  58. Anatomical and cellular basis of immunity and tolerance in the intestine.
    J Pediatr Gastroenterol Nutr. 2004 Jun;39 Suppl 3:S723-4 PMID: 15167360
  59. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization.
    Clin Exp Allergy. 2005 Apr;35(4):539-46 PMID: 15836765
  60. Lactic acid bacteria as live vaccines.
    Curr Issues Mol Biol. 2000 Jan;2(1):17-25 PMID: 11464916
  61. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract.
    Appl Environ Microbiol. 1995 Jul;61(7):2771-4 PMID: 7618890
  62. Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells.
    Microbes Infect. 2005 May;7(5-6):836-44 PMID: 15878681
  63. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.
    Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11672-7 PMID: 12972635
  64. IgA adaptation to the presence of commensal bacteria in the intestine.
    Curr Top Microbiol Immunol. 2006;308:117-36 PMID: 16922088
  65. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice.
    Int J Cancer. 2006 Oct 1;119(7):1702-9 PMID: 16646080
  66. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
    Nat Biotechnol. 2003 Jul;21(7):785-9 PMID: 12808464
  67. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice.
    J Virol. 2006 Apr;80(8):4079-87 PMID: 16571824
  68. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells.
    Inflamm Bowel Dis. 2005 Oct;11(10):865-71 PMID: 16189415
  69. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
    Gastroenterology. 2000 Dec;119(6):1461-72 PMID: 11113067
  70. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli.
    Immunology. 2000 Aug;100(4):510-8 PMID: 10929079
  71. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin.
    J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):512-20 PMID: 16284525
  72. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.
    Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9 PMID: 16716759
  73. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus.
    Vaccine. 2007 Jan 15;25(5):902-11 PMID: 17028078
  74. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen.
    J Drug Target. 2003;11(8-10):489-93 PMID: 15203917
  75. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase.
    Inflamm Bowel Dis. 2006 Nov;12(11):1044-52 PMID: 17075345
  76. Novel vaccines and adjuvants for allergen-specific immunotherapy.
    Curr Opin Immunol. 2006 Dec;18(6):761-8 PMID: 17010585
  77. Delivery systems and adjuvants for oral vaccines.
    Expert Opin Drug Deliv. 2006 Nov;3(6):747-62 PMID: 17076597
  78. In situ delivery of cytokines by genetically engineered Lactococcus lactis.
    Antonie Van Leeuwenhoek. 2002 Aug;82(1-4):323-31 PMID: 12369199
  79. Relationship between interaction sites in the gut, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria.
    J Appl Microbiol. 2004;96(2):230-43 PMID: 14723684
  80. The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies.
    Allergy. 2004 Jan;59(1):5-14 PMID: 14674927
  81. Heterologous protein production and delivery systems for Lactococcus lactis.
    Genet Mol Res. 2003 Mar 31;2(1):102-11 PMID: 12917806
  82. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.
    Allergy. 2006 Jul;61(7):812-9 PMID: 16792578
  83. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Respir Res. 2007 Aug 05;8:57 PMID: 17683588
  84. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.
    AIDS. 2001 Mar 30;15(5):621-7 PMID: 11317000
  85. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.
    Gastroenterology. 2004 Aug;127(2):502-13 PMID: 15300583
  86. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci.
    J Med Microbiol. 2004 May;53(Pt 5):427-433 PMID: 15096553
  87. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    J Immunol. 2005 Dec 1;175(11):7297-302 PMID: 16301635
  88. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses.
    Clin Exp Immunol. 2001 Oct;126(1):2-8 PMID: 11678893
  89. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice.
    J Appl Microbiol. 2005;99(5):1158-64 PMID: 16238746
  90. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli.
    AIDS. 2006 Oct 3;20(15):1917-22 PMID: 16988512
  91. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Infect Immun. 2004 Jun;72(6):3444-50 PMID: 15155651
  92. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection.
    J Infect Dis. 2007 Jan 15;195(2):185-93 PMID: 17191163
  93. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption.
    Appl Environ Microbiol. 1999 Jan;65(1):351-4 PMID: 9872808
  94. Lactobacillus acidophilus expressing recombinant K99 adhesive fimbriae has an inhibitory effect on adhesion of enterotoxigenic Escherichia coli.
    Microbiol Immunol. 2005;49(11):941-8 PMID: 16301804
  95. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.
    J Infect Dis. 2006 Aug 1;194(3):331-40 PMID: 16826481
  96. Probiotics for the treatment of women with bacterial vaginosis.
    Clin Microbiol Infect. 2007 Jul;13(7):657-64 PMID: 17633390
  97. Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism.
    J Med Microbiol. 2005 Nov;54(Pt 11):1093-1101 PMID: 16192442
  98. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer.
    J Immunol. 2006 May 1;176(9):5627-36 PMID: 16622032
  99. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria.
    Nat Biotechnol. 2000 Oct;18(10):1060-4 PMID: 11017043
  100. Immunomodulatory effects of probiotics in the intestinal tract.
    Curr Issues Mol Biol. 2008;10(1-2):37-54 PMID: 18525105
  101. Biotechnological applications for surface-engineered bacteria.
    Biotechnol Appl Biochem. 2004 Dec;40(Pt 3):209-28 PMID: 15035661
  102. The processing of antigens delivered as DNA vaccines.
    Immunol Rev. 2004 Jun;199:27-39 PMID: 15233724
Article Info
Journal
Nature reviews. Microbiology
Abbr.
Nat Rev Microbiol
ISSN
1740-1534
DOI
10.1038/nrmicro1840
Email
[email protected]
Published
2008-05-00
Pages
349-62
Language
English
Region
England
NLM ID
101190261
PMCID
PMC7096801
Subset
IM
External Links
PubMed source DOI: 10.1038/nrmicro1840 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2